The TLR players | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1481 of 1535  at  7/20/2019 8:00:51 PM  by


The following message was updated on 7/20/2019 8:06:27 PM.

 In response to msg 1479 by  vorlon1966
view thread

Re: The TLR players

 All good points.
 BMS is supplying Yervoy and Opdivo in the Illuminate-206 at their cost.

ILLUMINATE 206 – Phase 2, multi-center trial to test the safety and effectiveness of tilsotolimod in combination with ipilimumab and nivolumab in treating patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Microsatellite Stable Colorectal Cancer (MSS-CRC).

  • On March 11, 2019 entered into a second clinical trial collaboration with Bristol-Myers Squibb (BMS) in which BMS has agreed to manufacture and supply YERVOY (ipilimumab) and OPDIVO (nivolumab) at its cost and for no charge for use in ILLUMINATE-206;
  • Received notice from the U.S. Food and Drug Administration that we can proceed to implement the ILLUMINATE-206 clinical trial under a new Investigational New Drug (IND) application; and
  • Both trial cohorts of SCCHN and MSS-CRC expected to initiate in the second quarter of 2019.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 109
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
1482 Re: The TLR players vorlon1966 0 7/20/2019 10:53:14 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by